Premium
Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high‐dose cisplatin‐based chemoradiotherapy
Author(s) -
Driessen Chantal M. L.,
Leijendeckers Joop,
Snik Ad,
van der Graaf Winette T. A.,
de Boer Jan Paiul,
Gelderblom Hans,
Kaanders Johannes H. A. M.,
Takes Robert,
van Herpen Carla M. L.
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25434
Subject(s) - ototoxicity , medicine , cisplatin , concomitant , chemoradiotherapy , docetaxel , head and neck cancer , radiation therapy , chemotherapy , induction chemotherapy , fluorouracil , oncology , surgery , urology
Background This study evaluated ototoxicity in locally advanced head and neck cancer patients treated in the CONDOR study with docetaxel/cisplatin/5‐fluorouracil (TPF) followed by conventional radiotherapy with concomitant cisplatin 100 mg/m 2 on days 1, 22, and 43 (cis100+RT) versus accelerated radiotherapy with concomitant cisplatin weekly 40 mg/m 2 (cis40+ART). Methods Sixty‐two patients were treated in this study. Audiometry was performed at baseline, during TPF, before start of chemoradiotherapy, and 1, 4, 8, and 12 months after treatment. Results A complete dataset of audiometric data was available of 12 patients treated with high‐dose cisplatin and of 11 patients treated with intermediate‐dose cisplatin. Patients in the high‐dose group showed significant more hearing loss than in the intermediate group at 4 kHz ([ z = 1.98; P = .04] and 8 kHz [ z = 2.07; P < .03]). Interindividual variation was high in both groups. Conclusion After induction TPF, more ototoxicity was observed in chemoradiotherapy with cis100+RT than after chemoradiotherapy with cis40+ART.